Followers | 0 |
Posts | 1151 |
Boards Moderated | 0 |
Alias Born | 07/10/2003 |
Monday, September 01, 2003 7:59:57 AM
Heres a little info. on RIBI -
Ribi ImmunoChem Research, Inc. develops biopharmaceutical products that stimulate the immune system to generate natural agents and signals to prevent and treat human diseases. The company researches, develops, produces and markets these products some of which are under investigation by other companies for use as adjuvants. The company also manufactures clinical products and develops processes for the commercial scale production of its compounds. The company's technology is based on potent capacities of certain microbial products to modulate the cytokine cascade in man and other animals. The product development of the company is the use of MPL immunomodulator in combination with other immunomodulator. The company's product, human biopharmaceutical is being regulated by the FDA, which requires to be tested for the use of human treatment. The company has 20 research products to date. The company has been using its research products to develop immunotherapeutic agents for the treatment of malignant tumors and other diseases. The company has spent approximately $237,000 towards year 2000 expenses. Contracts & licences accounted for 53% of 1998 revenues & biopharmaceutical products, 47%.
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • Oct 1, 2024 7:00 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM